

Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market - Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/H70E1704A486EN.html>

Date: January 2022

Pages: 74

Price: US\$ 3,250.00 (Single User License)

ID: H70E1704A486EN

Abstracts

The immunoglobulin combination was separated and extracted from normal human plasma by the low-temperature ethanol method, and refined through further processing and virus inactivation steps. This product is a complete, unmodified natural IgG antibody with a purity of up to 98%. It contains no preservatives and antibiotics and is intended for intravenous infusion. Compared with intramuscular gamma globulin, it has a faster effect and a significant effect. advantage.

This report contains market size and forecasts of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in global, including the following market information:

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) companies in 2021 (%)

The global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

1g/20ml Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market, by Type, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Segment Percentages, by Type, 2021 (%)

1g/20ml

1.25g/25ml

2.5g/50ml

5g/100ml

10g/200ml

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market, by Application, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Others

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions) & (K Units)

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) revenues in global market, 2017-2022 (Estimated), (\$ millions)

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) revenues share in global market, 2021 (%)

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) sales in global market, 2017-2022 (Estimated), (K Units)

Key companies Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Boya-Bio

Beijing Tiantan Biological Products

Hualan Bio

Guangdong Shuagnlin Bio-pharmacy

Weiguang Biological

Sinopharm

Shanghai RAAS

CTBB

Nanyue Biopharming

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL HUMAN IMMUNOGLOBULIN(PH4) FOR INTRAVENOUS INJECTION(COVID-19) OVERALL MARKET SIZE

- 2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size: 2021 VS 2028
- 2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, Prospects & Forecasts: 2017-2028
- 2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales: 2017-2028

3 COMPANY LANDSCAPE

- 3.1 Top Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Players in Global Market
- 3.2 Top Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Companies Ranked by Revenue
- 3.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Companies
- 3.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Companies
- 3.5 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Manufacturer (2017-2022)

3.6 Top 3 and Top 5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Companies in Global Market, by Revenue in 2021

3.7 Global Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Type

3.8 Tier 1, Tier 2 and Tier 3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Players in Global Market

3.8.1 List of Global Tier 1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Companies

3.8.2 List of Global Tier 2 and Tier 3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Companies

4 SIGHTS BY PRODUCT

4.1 Overview

4.1.1 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Markets, 2021 & 2028

4.1.2 1g/20ml

4.1.3 1.25g/25ml

4.1.4 2.5g/50ml

4.1.5 5g/100ml

4.1.6 10g/200ml

4.2 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue & Forecasts

4.2.1 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2017-2022

4.2.2 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2023-2028

4.2.3 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

4.3 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales & Forecasts

4.3.1 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, 2017-2022

4.3.2 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, 2023-2028

4.3.3 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

4.4 By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (Manufacturers Selling Prices), 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Others

5.2 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue & Forecasts

5.2.1 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2017-2022

5.2.2 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2023-2028

5.2.3 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

5.3 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales & Forecasts

5.3.1 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, 2017-2022

5.3.2 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, 2023-2028

5.3.3 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

5.4 By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (Manufacturers Selling Prices), 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2021 & 2028

6.2 By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue & Forecasts

6.2.1 By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2017-2022

6.2.2 By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2023-2028

6.2.3 By Region - Global Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Revenue Market Share, 2017-2028

6.3 By Region - Global Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Sales & Forecasts

6.3.1 By Region - Global Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Sales, 2017-2022

6.3.2 By Region - Global Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Sales, 2023-2028

6.3.3 By Region - Global Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Sales Market Share, 2017-2028

6.4 North America

6.4.1 By Country - North America Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Revenue, 2017-2028

6.4.2 By Country - North America Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Sales, 2017-2028

6.4.3 US Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market
Size, 2017-2028

6.4.4 Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Market Size, 2017-2028

6.4.5 Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Market Size, 2017-2028

6.5 Europe

6.5.1 By Country - Europe Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Revenue, 2017-2028

6.5.2 By Country - Europe Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Sales, 2017-2028

6.5.3 Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Market Size, 2017-2028

6.5.4 France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Market Size, 2017-2028

6.5.5 U.K. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market
Size, 2017-2028

6.5.6 Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market
Size, 2017-2028

6.5.7 Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Market Size, 2017-2028

6.5.8 Nordic Countries Human Immunoglobulin(pH4) for Intravenous
Injection(COVID-19) Market Size, 2017-2028

6.5.9 Benelux Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Market Size, 2017-2028

6.6 Asia

6.6.1 By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2017-2028

6.6.2 By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, 2017-2028

6.6.3 China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.6.4 Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.6.5 South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.6.6 Southeast Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.6.7 India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.7 South America

6.7.1 By Country - South America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2017-2028

6.7.2 By Country - South America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, 2017-2028

6.7.3 Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.7.4 Argentina Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.8 Middle East & Africa

6.8.1 By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2017-2028

6.8.2 By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, 2017-2028

6.8.3 Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.8.4 Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.8.5 Saudi Arabia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

6.8.6 UAE Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size, 2017-2028

7 MANUFACTURERS & BRANDS PROFILES

7.1 Boya-Bio

7.1.1 Boya-Bio Corporate Summary

7.1.2 Boya-Bio Business Overview

7.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Major Product Offerings

7.1.4 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Sales and Revenue in Global (2017-2022)

7.1.5 Boya-Bio Key News

7.2 Beijing Tiantan Biological Products

7.2.1 Beijing Tiantan Biological Products Corporate Summary

7.2.2 Beijing Tiantan Biological Products Business Overview

7.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Major Product Offerings

7.2.4 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales and Revenue in Global (2017-2022)

7.2.5 Beijing Tiantan Biological Products Key News

7.3 Hualan Bio

7.3.1 Hualan Bio Corporate Summary

7.3.2 Hualan Bio Business Overview

7.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Major Product Offerings

7.3.4 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Sales and Revenue in Global (2017-2022)

7.3.5 Hualan Bio Key News

7.4 Guangdong Shuagnlin Bio-pharmacy

7.4.1 Guangdong Shuagnlin Bio-pharmacy Corporate Summary

7.4.2 Guangdong Shuagnlin Bio-pharmacy Business Overview

7.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Major Product Offerings

7.4.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales and Revenue in Global (2017-2022)

7.4.5 Guangdong Shuagnlin Bio-pharmacy Key News

7.5 Weiguang Biological

7.5.1 Weiguang Biological Corporate Summary

7.5.2 Weiguang Biological Business Overview

7.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Major Product Offerings

7.5.4 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Sales and Revenue in Global (2017-2022)

7.5.5 Weiguang Biological Key News

7.6 Sinopharm

7.6.1 Sinopharm Corporate Summary

7.6.2 Sinopharm Business Overview

7.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Major Product Offerings

7.6.4 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Sales and Revenue in Global (2017-2022)

7.6.5 Sinopharm Key News

7.7 Shanghai RAAS

7.7.1 Shanghai RAAS Corporate Summary

7.7.2 Shanghai RAAS Business Overview

7.7.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Major Product Offerings

7.7.4 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Sales and Revenue in Global (2017-2022)

7.7.5 Shanghai RAAS Key News

7.8 CTBB

7.8.1 CTBB Corporate Summary

7.8.2 CTBB Business Overview

7.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Major Product Offerings

7.8.4 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales and Revenue in Global (2017-2022)

7.8.5 CTBB Key News

7.9 Nanyue Biopharming

7.9.1 Nanyue Biopharming Corporate Summary

7.9.2 Nanyue Biopharming Business Overview

7.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Major Product Offerings

7.9.4 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales and Revenue in Global (2017-2022)

7.9.5 Nanyue Biopharming Key News

8 GLOBAL HUMAN IMMUNOGLOBULIN(PH4) FOR INTRAVENOUS INJECTION(COVID-19) PRODUCTION CAPACITY, ANALYSIS

8.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)

Production Capacity, 2017-2028

8.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Capacity of Key Manufacturers in Global Market

8.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production by Region

9 KEY MARKET TRENDS, OPPORTUNITY, DRIVERS AND RESTRAINTS

9.1 Market Opportunities & Trends

9.2 Market Drivers

9.3 Market Restraints

10 HUMAN IMMUNOGLOBULIN(PH4) FOR INTRAVENOUS INJECTION(COVID-19) SUPPLY CHAIN ANALYSIS

10.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Value Chain

10.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Upstream Market

10.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Downstream and Clients

10.4 Marketing Channels Analysis

10.4.1 Marketing Channels

10.4.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors and Sales Agents in Global

11 CONCLUSION

12 APPENDIX

12.1 Note

12.2 Examples of Clients

12.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Key Players of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) in Global Market

Table 2. Top Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Players in Global Market, Ranking by Revenue (2021)

Table 3. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Companies, (US\$, Mn), 2017-2022

Table 4. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Companies, 2017-2022

Table 5. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Companies, (K Units), 2017-2022

Table 6. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Companies, 2017-2022

Table 7. Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (2017-2022) & (US\$/Unit)

Table 8. Global Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Type

Table 9. List of Global Tier 1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (US\$, Mn), 2017-2022

Table 13. By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (US\$, Mn), 2023-2028

Table 14. By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), 2017-2022

Table 15. By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), 2023-2028

Table 16. By Application – Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2021 & 2028

Table 17. By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (US\$, Mn), 2017-2022

Table 18. By Application - Global Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Revenue (US\$, Mn), 2023-2028

Table 19. By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), 2017-2022

Table 20. By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), 2023-2028

Table 21. By Region – Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2021 VS 2028

Table 22. By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (US\$, Mn), 2017-2022

Table 23. By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (US\$, Mn), 2023-2028

Table 24. By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), 2017-2022

Table 25. By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), 2023-2028

Table 26. By Country - North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2017-2022

Table 29. By Country - North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2023-2028

Table 30. By Country - Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2022

Table 31. By Country - Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2023-2028

Table 32. By Country - Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2017-2022

Table 33. By Country - Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2023-2028

Table 34. By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2022

Table 35. By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2023-2028

Table 36. By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2017-2022

Table 37. By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2023-2028

Table 38. By Country - South America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2022

Table 39. By Country - South America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2023-2028

Table 40. By Country - South America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2017-2022

Table 41. By Country - South America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2023-2028

Table 42. By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2022

Table 43. By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2023-2028

Table 44. By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2017-2022

Table 45. By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, (K Units), 2023-2028

Table 46. Boya-Bio Corporate Summary

Table 47. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings

Table 48. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 49. Beijing Tiantan Biological Products Corporate Summary

Table 50. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings

Table 51. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 52. Hualan Bio Corporate Summary

Table 53. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings

Table 54. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 55. Guangdong Shuagnlin Bio-pharmacy Corporate Summary

Table 56. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings

Table 57. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)

Table 58. Weiguang Biological Corporate Summary

Table 59. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings
Table 60. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
Table 61. Sinopharm Corporate Summary
Table 62. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings
Table 63. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
Table 64. Shanghai RAAS Corporate Summary
Table 65. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings
Table 66. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
Table 67. CTBB Corporate Summary
Table 68. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings
Table 69. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
Table 70. Nanyue Biopharming Corporate Summary
Table 71. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Offerings
Table 72. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (US\$, Mn) and Average Price (US\$/Unit) (2017-2022)
Table 73. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Capacity (K Units) of Key Manufacturers in Global Market, 2020-2022 (K Units)
Table 74. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Capacity Market Share of Key Manufacturers, 2020-2022
Table 75. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production by Region, 2017-2022 (K Units)
Table 76. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production by Region, 2023-2028 (K Units)
Table 77. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Opportunities & Trends in Global Market
Table 78. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Drivers in Global Market

Table 79. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market
Restraints in Global Market

Table 80. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Raw
Materials

Table 81. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Raw
Materials Suppliers in Global Market

Table 82. Typical Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Downstream

Table 83. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Downstream Clients in Global Market

Table 84. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
Distributors and Sales Agents in Global Market

List Of Figures

LIST OF FIGURES

Figure 1. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Type

Figure 2. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Application

Figure 3. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, 2017-2028 (US\$, Mn)

Figure 7. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales in Global Market: 2017-2028 (K Units)

Figure 8. The Top 3 and 5 Players Market Share by Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue in 2021

Figure 9. By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 10. By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 11. By Type - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (US\$/Unit), 2017-2028

Figure 12. By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 13. By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 14. By Application - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (US\$/Unit), 2017-2028

Figure 15. By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 16. By Region - Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 17. By Country - North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 18. By Country - North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 19. US Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 20. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 21. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 22. By Country - Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 23. By Country - Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 24. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 25. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 26. U.K. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 27. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 28. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 29. Nordic Countries Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 30. Benelux Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 31. By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 32. By Region - Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 33. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 34. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 35. South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 36. Southeast Asia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 37. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 38. By Country - South America Human Immunoglobulin(pH4) for Intravenous

Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 39. By Country - South America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 40. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 41. Argentina Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 42. By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share, 2017-2028

Figure 43. By Country - Middle East & Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share, 2017-2028

Figure 44. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 45. Israel Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 46. Saudi Arabia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 47. UAE Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US\$, Mn), 2017-2028

Figure 48. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Production Capacity (K Units), 2017-2028

Figure 49. The Percentage of Production Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region, 2021 VS 2028

Figure 50. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Value Chain

Figure 51. Marketing Channels

I would like to order

Product name: Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market - Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/H70E1704A486EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/H70E1704A486EN.html>